Migalastat hydrochloride

Names

[ Name ]:
Migalastat hydrochloride

[Synonym ]:
(1R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidinium chloride
1,5-dideoxy-1,5-imino-D-glucitol hydrochloride
1-Deoxymannojirimycinehydrochloride
DEOXYMANNONOJIRIMYCIN HCL
(+)-(2R,3R,4R,5S)-2-hydroxymethyl-3,4,5-trihydroxypiperidine hydrochloride
DEOXYMANNOJIRIMYCIN,HYDROCHLORIDE
(+)-1-deoxynojirimycin hydrochloride
1-DEOXYMANNOJIRIMYCIN HCL
DMM
DEOXYMANNOJIRIMYCIN HCL
DMJ,HYDROCHLORIDE
1-DeoxymannojirimycineHCl
Migalastat (hydrochloride)

Biological Activity

[Description]:

Migalastat hydrochloride (1-Deoxygalactonojirimycin hydrochloride) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Others

[Target]

IC50: 0.04 μM (human α-Gal A)[1];Ki: 0.04 μM (human α-Gal A)[1]

[In Vitro]

Both IC50 and Ki values of migalastat hydrochloride toward human lysosomal a-Gal A are 0.04 μM[1].

[In Vivo]

Fabry disease is an X-linked recessive disorder caused by the deficient activity of α-galactosidase A. α-Gal A activity in heart, kidney, spleen, and liver is increased dose- and time-dependently in transgenic mice that express human mutant alpha-Gal A with migalastat hydrochloride treatment. The half-life of DGJ is less than 1 day in all major issues and that of the enzyme synthesized during the DGJ treatment period is approximately 4 days[2]. Oral administration of migalastat hydrochloride reduces tissue GL-3 in fabry transgenic mice, and in urine and kidneys of some FD patients. Oral administration of migalastat hydrochloride to transgenic mice reduces elevated lyso-Gb3 levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively, generally equal to or greater than observed for GL-3[3].

[Animal admin]

Mice: Migalastat hydrochloride is dissolved in drinking water. Age-matched male homozygous TgM, TgM/KO, and nontransgenic (Non-Tg) C57BL/6 mice are supplied drinking water containing DGJ ad libitum. Body weight is monitored weekly during the DGJ treatment period. Average daily DGJ dosage is estimated based on the consumption of drinking water. Mice fed drinking water containing DGJ at 0.05 mM typically received DGJ at approximately 3 mg/kg body weight/day[2].

[References]

[1]. Asano N, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000 Jul;267(13):4179-86.

[2]. Ishii S, et al. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J Pharmacol Exp Ther. 2009 Mar;328(3):723-31.

[3]. Young-Gqamana B, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One. 2013;8(3):e57631.

[Related Small Molecules]

Chemical & Physical Properties

[ Boiling Point ]:
382.7ºC at 760 mmHg

[ Melting Point ]:
260ºC

[ Molecular Formula ]:
C₆H₁₄ClNO₄

[ Molecular Weight ]:
199.63300

[ Flash Point ]:
185.2ºC

[ Exact Mass ]:
199.06100

[ PSA ]:
92.95000

Safety Information

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
26-36

[ RIDADR ]:
NONH for all modes of transport

Articles

Paulsen, H., et al.

Chem. Ber. 113 , 2601, (1980)

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.